Redant, fair comments and I can see where you are coming from but I have reservations about the current strategy. IMO proceeding with the Phase 2 vax trials now will place undue pressure on the financial stability of the company and more than likely result in another CR this year. Put simply with the current cash burn of $10m in the last 6 months the company does not have enough cash to fund operations and vax trials. A CR will result in a lower SP and dilution which is not in the interests of shareholders. The company should be partnering now at Phase 1 with the big pharma paying all Phase 2,3 and FDA submission costs.
Redant, fair comments and I can see where you are coming from...
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$11.48 |
Change
-0.020(0.17%) |
Mkt cap ! $233.8M | |||
| Open | High | Low | Value | Volume |
| $11.50 | $11.50 | $10.91 | $152.9K | 13.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 257 | $11.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $11.48 | 135 | 1 |
View Market Depth
| Last trade - 16.10pm 17/10/2024 (20 minute delay) ? |
| AVR (ASX) Chart |